Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4905304 | 0.99 | HTR1A (0.48) | HTR1ASMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL4781452 | 0.97 | HTR1A (0.52) | HTR1ASMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL5745908 | 0.80 | HTR1A (0.52) | HTR1ASMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL5744144 | 0.79 | HTR1A (0.47) | HTR1ASMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL27668975 | 0.79 | HTR1A (0.55) | HTR1ASMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL5745668 | 0.78 | HTR1A (0.63) | HTR1ASMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL4903670 | 0.78 | HTR1A (0.54) | HTR1A | |
| SCHEMBL4905316 | 0.77 | HTR1A (0.53) | HTR1A | |
| SCHEMBL4781457 | 0.74 | HTR1A (0.57) | HTR1A | |
| SCHEMBL5746794 | 0.74 | HTR1A (0.60) | HTR1ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200470-A1 | Diaza- or Thiazadione Derivatives With Neuroprotective Activity | SCHWARTZ PHARMA S.L | 2008-08-21 | — | — | US | claimed |
| US-20080200470-A1 | Diaza- or Thiazadione Derivatives With Neuroprotective Activity | SCHWARTZ PHARMA S.L | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200470-A1 | Diaza- or Thiazadione Derivatives With Neuroprotective Activity | HTR1A, HTR3A, HTR2A | HTR1A 1/4885SMN1; SMN2 517/4885MEN1 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.